Drug intelligence / Profile preview

aleglitazar + aspirin

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Aleglitazar + aspirin refers to the co-administration of *aleglitazar*, a dual peroxisome proliferator-activated receptor alpha/gamma (PPAR-α/γ) agonist, and *aspirin*, an antiplatelet agent. Aleglitazar was developed primarily for glycemic and lipid control in type 2 diabetes and for potential cardiovascular benefit, while aspirin is widely used for its antithrombotic properties. The combination has been studied in healthy volunteers to assess potential pharmacokinetic interactions, focusing on safety and tolerability[5][6][7].

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on aleglitazar + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aleglitazar + aspirin.

Explore the full profile